Screened September 29, 2026 · TSX: GUD · Q2 2026 (quarter ended June 30, 2026)

Is Knight Therapeutics (GUD) halal?

Knight Therapeutics (TSX: GUD) is a Montreal specialty pharmaceutical company with no haram business segment. Interest-bearing debt of ~C$34.3 million is about 3.4% of the ~C$1.01 billion market cap (under the ~33% ceiling), and interest income of ~C$0.901 million is about 0.62% of Q2 2026 revenue of C$144.212 million (under the ~5% ceiling). This screener is a PASS.

The two-gate Shariah screen

Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).

Gate one: the business — passes

Knight Therapeutics, headquartered in Montreal, is a specialty pharmaceutical company focused on acquiring, in-licensing, developing and commercializing pharmaceutical products for Canada and Latin America (pan-American, ex-US). LATAM subsidiaries operate as United Medical, Biotoscana Farma and Laboratorio LKM. Its portfolio spans oncology, hematology, infectious diseases and other specialty medicines (Jornay PM, Xcopri, Orgovyx, Myfembree, Cresemba, Minjuvi, Tavalisse, Pemazyre, Lenvima, Ambisome), plus consumer health products and medical devices. One nuance worth noting: the company also provides financing to other life sciences companies "to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights" — an interest-generating activity, but interest income stays at ~0.62% of revenue, below the ~5% ceiling. No alcohol, gambling, conventional banking/insurance, or weapons segments were found. The business gate passes.

Gate two: the ratios — both pass

Balance sheet at June 30, 2026 (Q2 2026 release, all CAD): bank loans of C$23.1 million + lease liabilities of C$11.1 million = ~C$34.3 million of interest-bearing debt. Cash & equivalents of C$93.5M plus marketable securities of C$16.1M = C$109.6M (net cash C$87M). The revolving credit facility used to fund the Paladin Labs acquisition (~C$107M, June 2025) was repaid in full in June 2026; a US$100M revolver plus a US$100M accordion remains available. With ~98.2 million shares outstanding at ~C$10.26–10.35 (September 29, 2026), the market cap is about C$1.01 billion — debt is about 3.4% of market cap, well under the ~33% ceiling. Interest income of C$0.901 million on financial instruments at amortized cost (H1: C$1.853M, ~0.63%) is about 0.62% of Q2 2026 revenue of C$144.212 million (H1 revenue C$292.651M; 2026 guidance raised to C$540–560M) — under the ~5% ceiling. Both ratios pass.

What other screeners say

No coverage pages were found for GUD/GUD.TO on Zoya, Musaffa, or ShariaPortfolio in targeted searches as of September 29, 2026 (Musaffa "GUD" ticker pages relate to other securities, not Knight). This screener is based on Knight's Q2 2026 financials.

The bottom line

This screener gives Knight Therapeutics Inc. (TSX: GUD) a PASS. A clean specialty-pharma business with debt at about 3.4% of market cap and interest income at about 0.62% of revenue — on a net-cash balance sheet after the Paladin facility was repaid. 2026 milestones to watch: Tavalisse approvals in Brazil/Colombia, Health Canada approval for Wynzora, and the NCIB renewal (2.02M shares already repurchased at ~C$5.48 avg). Consult a qualified scholar. Snapshot dated September 29, 2026; re-checked quarterly after earnings.

Sources

• Q2 2026 results (Knight Therapeutics, GlobeNewswire, Aug 6, 2026)

Frequently asked questions